Patterson Joshua F. 4

What Happened

• Joshua F. Patterson, General Counsel and Chief Compliance Officer of CG Oncology (CGON), received an award of 45,266 derivative shares on April 15, 2026. The grant price is listed as $0.00 (no cash paid at grant) and is reported as an award/other acquisition (code A). This is a grant of equity subject to vesting, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-15; filing date (Form 4): 2026-04-16 (timely).
• Amount: 45,266 shares granted at $0.00 per share (derivative award).
• Shares owned after transaction: Not specified in this filing.
• Vesting: 1/48th of the shares vest monthly beginning April 15, 2026, subject to continuous service (per footnote).
• Transaction type: Award of derivative shares (not an immediate sale or purchase).

Context

• This grant appears to be a time-based equity award (commonly RSUs or similar) that vests monthly over 48 months; Patterson will realize value only as shares vest and/or are sold. Because no cash was exchanged at grant, the reported dollar value at grant is $0.00 on the Form 4. Such awards are standard executive compensation and do not by themselves indicate immediate buying or selling activity.